Literature DB >> 8106631

Serum interleukin-6 in amiodarone-induced thyrotoxicosis.

L Bartalena1, L Grasso, S Brogioni, F Aghini-Lombardi, L E Braverman, E Martino.   

Abstract

Amiodarone, an iodine-rich cardiac drug, may induce thyrotoxicosis (AIT), which can occur in patients with preexisting thyroid abnormalities and in subjects with apparently normal thyroid glands. The pathogenesis of AIT is often due to iodine-induced excessive thyroid hormone synthesis, especially in patients with underlying thyroid disease. In some instances, however, AIT may be related to a destructive process due to amiodarone-induced thyroiditis, resulting in thyroid cell damage and thyroid hormone release into the circulation. Another thyroid inflammatory process, subacute thyroiditis, has been recently reported to be associated with markedly increased serum interleukin-6 (IL-6) levels. To investigate the significance of serum IL-6 levels in AIT, we evaluated in a cross-sectional study the following subjects: 27 AIT patients, 15 with no apparent thyroid abnormalities (AIT-) and 12 with nodular goiter and/or thyroid autoimmune disease (AIT+); 14 euthyroid patients receiving chronic amiodarone therapy; 10 patients with amiodarone-induced hypothyroidism; 56 patients with spontaneous hyperthyroidism due to Graves' disease (n = 35) or toxic adenoma/nodular goiter (n = 21); 20 subjects with nontoxic goiter; and 50 healthy controls. Serum free thyroid hormone concentrations did not differ in patients with amiodarone-induced or spontaneous hyperthyroidism. Mean (+/- SE) serum IL-6 values were as follows: AIT-, 573.5 +/- 78.7 fmol/L (range, 149.4-1145.1); AIT+, 152.7 +/- 46.3 fmol/L (range, < 25-505.6); euthyroid patients receiving chronic amiodarone therapy, 51.4 +/- 10.0 fmol/L (range, < 25-122.5); amiodarone-induced hypothyroidism, 43.8 +/- 8.4 fmol/L (range, < 25-84.3); Graves' disease, 108.2 +/- 18.2 fmol/L (range, < 25-250); toxic adenoma/nodular goiter, 97.6 +/- 10.3 fmol/L (range, < 25-168.9); nontoxic goiter, 47.3 +/- 7.1 fmol/L (range, < 25-106.6); and controls, 37.8 +/- 6.2 fmol/L (range, < 25-99.4). Serum IL-6 values in AIT- patients were markedly higher (P < 0.0001) than those in all other groups. Values in AIT+, although slightly higher, did not significantly differ from those in patients with spontaneous hyperthyroidism. AIT- patients had low 24-h thyroidal radioiodine uptake (RAIU), whereas AIT+ had inappropriately low normal to high (9-58%) RAIU values in the presence of excess iodine. The presence of markedly elevated serum IL-6 concentrations and low thyroidal RAIU values in patients with AIT without underlying thyroid disease suggests the presence of amiodarone-induced thyroiditis as the etiology of thyrotoxicosis. Treatment of 2 such patients with prednisone was associated with a dramatic reduction and prompt normalization of IL-6 and thyroid hormone values.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8106631     DOI: 10.1210/jcem.78.2.8106631

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

Review 1.  Iodine effects on the thyroid gland: biochemical and clinical aspects.

Authors:  K D Burman; L Wartofsky
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

2.  Atrial fibrillation due to late amiodarone-induced thyrotoxicosis.

Authors:  Ibrahim Halil Kurt; Talat Yigit; Bulent Mustafa Karademir
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 3.  Amiodarone-induced thyroid disorders: a clinical review.

Authors:  K C Loh
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

4.  Amiodarone-induced thyrotoxicosis: type 1 or type 2?

Authors:  Ahsan Khan; Amar Puttanna; Diana Raskauskiene
Journal:  BMJ Case Rep       Date:  2014-10-27

5.  High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment.

Authors:  S Mariotti; A Loviselli; S Murenu; F Sau; L Valentino; A Mandas; S Vacquer; E Martino; A Balestrieri; M E Lai
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

6.  Management of amiodarone-related thyroid problems.

Authors:  Shashithej K Narayana; David R Woods; Christopher J Boos
Journal:  Ther Adv Endocrinol Metab       Date:  2011-06       Impact factor: 3.565

7.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  Andrea Hofmann; Clemens Nawara; Sedat Ofluoglu; Johannes Holzmannhofer; Bernhard Strohmer; Christian Pirich
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Sustained high levels of serum leptin rather than IL-6 observed in patients with postpartum thyroiditis during their first postpartum year.

Authors:  Huiling Guo; Xiu Liu; Chenyang Li; Yushu Li; Miao Sang; Zhongyan Shan; Weiping Teng; Haixia Guan
Journal:  Endocrine       Date:  2014-02-27       Impact factor: 3.633

9.  Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness.

Authors:  L Bartalena; S Brogioni; L Grasso; F Velluzzi; E Martino
Journal:  J Endocrinol Invest       Date:  1994-04       Impact factor: 4.256

10.  Coexistence of subacute thyroiditis and renal cell carcinoma: a paraneoplastic syndrome.

Authors:  Ekrem Algün; Süleyman Alici; Cevat Topal; Serdar Ugras; Reha Erkoç; M Emin Sakarya; Nese Ozbey
Journal:  CMAJ       Date:  2003-04-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.